These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1708317)

  • 101. Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer.
    Yiannakou JY; Newland P; Calder F; Kingsnorth AN; Rhodes JM
    Lancet; 1997 Feb; 349(9049):389-92. PubMed ID: 9033465
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Comparison of serological expression of different epitopes on the CA50-carrying antigen CanAg.
    Johansson C; Nilsson O; Lindholm L
    Int J Cancer; 1991 Jul; 48(5):757-63. PubMed ID: 1712758
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Serum ferritin in pancreatic disease. An accurate test of malignancy?
    Nitti D; Fabris C; Del Favero G; Farini R; Grassi F; Farini A; Baccaglini U; Pedrazzoli S; Piccoli A; Lise M; Naccarato R
    Digestion; 1982; 25(4):258-62. PubMed ID: 7166209
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases.
    Yue T; Partyka K; Maupin KA; Hurley M; Andrews P; Kaul K; Moser AJ; Zeh H; Brand RE; Haab BB
    Proteomics; 2011 Sep; 11(18):3665-74. PubMed ID: 21751362
    [TBL] [Abstract][Full Text] [Related]  

  • 105. The reliability of highly elevated CA 19-9 levels.
    Osswald BR; Klee FE; Wysocki S
    Dis Markers; 1993 Dec; 11(5-6):275-8. PubMed ID: 8082316
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Tumor markers CA 19-9 and CA 195 are also useful as markers for cystic fibrosis.
    Wu JT; Olson J; Walker K
    J Clin Lab Anal; 1992; 6(3):151-61. PubMed ID: 1506983
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Chromatographic characterization of CA 19-9 molecules from cystic fibrosis and pancreatic carcinoma.
    Wu JT; Chang J
    J Clin Lab Anal; 1992; 6(4):209-15. PubMed ID: 1383481
    [TBL] [Abstract][Full Text] [Related]  

  • 108. The value of routine biochemical tests in discriminating between malignant and benign pancreatic tumours.
    Athlin L; Blind PJ; Eriksson S
    HPB Surg; 1991 Jun; 4(2):147-53; discussion 153-5. PubMed ID: 1931781
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Serum beta 2-microglobulin in chronic diseases of the pancreas.
    Pezzilli R; Billi P; Fiocchi M; Beltrandi E; Cappelletti O; Sprovieri G; Miglioli M
    Int J Pancreatol; 1995 Apr; 17(2):161-6. PubMed ID: 7622938
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Serum protein profiles of patients with pancreatic cancer and chronic pancreatitis: searching for a diagnostic protein pattern.
    Valerio A; Basso D; Mazza S; Baldo G; Tiengo A; Pedrazzoli S; Seraglia R; Plebani M
    Rapid Commun Mass Spectrom; 2001; 15(24):2420-5. PubMed ID: 11746913
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Serum neurotensin in human pancreatic cancer.
    Meggiato T; Ferrara C; Tessari G; Plebani M; De Paoli M; Del Favero G; Naccarato R
    Tumori; 1996; 82(6):592-5. PubMed ID: 9061071
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Portal but not peripheral serum levels of interleukin 6 could interfere with glucose metabolism in patients with pancreatic cancer.
    Fogar P; Basso D; Pasquali C; Piva MG; Brigato L; De Paoli M; Galeotti F; Corsini A; Plebani M
    Clin Chim Acta; 1998 Oct; 277(2):181-9. PubMed ID: 9853701
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Hepatic changes and serum ferritin in pancreatic cancer and other gastrointestinal diseases: the role of cholestasis.
    Basso D; Fabris C; Del Favero G; Meggiato T; Panozzo MP; Vianello D; Plebani M; Naccarato R
    Ann Clin Biochem; 1991 Jan; 28 ( Pt 1)():34-8. PubMed ID: 2024931
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Plasma concentrations of CA-50 in relation to tumour burden in exocrine pancreatic cancer.
    Pålsson B; Andren-Sandberg A; Masson P
    Eur J Cancer; 1991; 27(10):1279-82. PubMed ID: 1835599
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.
    Masson P; Pålsson B; Andrén-Sandberg A
    Br J Cancer; 1990 Jul; 62(1):118-21. PubMed ID: 2390470
    [TBL] [Abstract][Full Text] [Related]  

  • 116. CA 19.9 in biliopancreatic diseases.
    Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Loizate Totoricagüena A
    Int J Biol Markers; 1989; 4(1):51-2. PubMed ID: 2746047
    [No Abstract]   [Full Text] [Related]  

  • 117. MCA and CA 15.3 serum levels in non-malignant diseases. Some preliminary results.
    Soriano A; Allende MT; Vizoso F; Fernández García J; Vivanco J; Ruibal A
    Int J Biol Markers; 1990; 5(1):46-7. PubMed ID: 2230351
    [No Abstract]   [Full Text] [Related]  

  • 118. Novel tumour markers: a diagnostic role in pancreatic cancer?
    Roulston JE
    Br J Cancer; 1994 Sep; 70(3):389-90. PubMed ID: 8080718
    [No Abstract]   [Full Text] [Related]  

  • 119. Study of the tumor marker carbohydrate antigen 50 in liver cirrhosis. Pathogenetic considerations.
    Collazos J; Genolla J; Ruibal A
    Clin Nucl Med; 1993 Jan; 18(1):56-9. PubMed ID: 8422722
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Utility of tumor marker CA 72.4 in patients with chronic renal failure.
    González Vitores AM; Encabo Duró G; Bermejo Fraile B; Olmos Miró A; Armengol Carrasco M
    Int J Biol Markers; 1999; 14(2):118-21. PubMed ID: 10399632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.